This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IceCure Medical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für IceCure Medical zu prognostizieren.

Wichtige Informationen

32.8%

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	22.3%
Wachstumsrate der Einnahmen	47.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	24 Jul 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

TASE:ICCM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	36	-1	-13	N/A	2
12/31/2024	11	-14	-21	N/A	4
12/31/2023	5	-16	-17	-15	4
3/31/2023	3	-16	-15	-14	N/A
12/31/2022	3	-17	-15	-14	N/A
9/30/2022	4	-16	-17	-16	N/A
6/30/2022	4	-15	-17	-16	N/A
3/31/2022	3	-13	-14	-14	N/A
12/31/2021	4	-10	-13	-13	N/A
9/30/2021	4	-8	-9	-8	N/A
6/30/2021	4	-6	-7	-6	N/A
3/31/2021	4	-4	-5	-5	N/A
12/31/2020	4	-4	-4	-4	N/A
9/30/2020	3	-4	-2	-2	N/A
6/30/2020	3	-4	-1	0	N/A
3/31/2020	2	-4	-1	-1	N/A
12/31/2019	2	-5	-2	-2	N/A
9/30/2019	1	-5	N/A	N/A	N/A
6/30/2019	1	-4	-4	-4	N/A
3/31/2019	1	-4	-4	-4	N/A
12/31/2018	1	-4	-3	-3	N/A
9/30/2018	1	-3	N/A	N/A	N/A
6/30/2018	1	-3	-3	-3	N/A
3/31/2018	1	-3	-3	-3	N/A
12/31/2017	1	-3	-3	-3	N/A
9/30/2017	1	-3	-3	-3	N/A
6/30/2017	1	-3	-3	-3	N/A
3/31/2017	1	-3	-3	-3	N/A
12/31/2016	1	-3	N/A	-3	N/A
9/30/2016	1	-3	N/A	-3	N/A
6/30/2016	1	-4	N/A	-4	N/A
3/31/2016	1	-4	N/A	-3	N/A
12/31/2015	1	-4	N/A	-3	N/A
9/30/2015	1	-4	N/A	-3	N/A
6/30/2015	1	-4	N/A	-3	N/A
3/31/2015	1	-4	N/A	-3	N/A
12/31/2014	1	-5	N/A	-3	N/A
9/30/2014	1	-5	N/A	-4	N/A
6/30/2014	1	-5	N/A	-4	N/A
3/31/2014	0	-5	N/A	-3	N/A
12/31/2013	0	-5	N/A	-3	N/A
9/30/2013	0	-5	N/A	-4	N/A
6/30/2013	0	-5	N/A	-4	N/A
3/31/2013	0	-5	N/A	-4	N/A
12/31/2012	0	-5	N/A	-4	N/A
9/30/2012	0	-4	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ICCM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ICCM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ICCM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ICCMDie Einnahmen des Unternehmens (47.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt IL (1.9% pro Jahr).

Hohe Wachstumseinnahmen: ICCMDie Einnahmen des Unternehmens (47.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ICCM in 3 Jahren voraussichtlich hoch sein wird

This company listing is no longer active

IceCure Medical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.35 loss in FY 2021)

Here's Why We're Watching IceCure Medical's (TLV:ICCM) Cash Burn Situation

IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump

IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems

IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.091 loss in 3Q 2021)

IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

Are Investors Undervaluing IceCure Medical Ltd (TLV:ICCM) By 29%?

IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense®

Second quarter 2022 earnings released

IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022

IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022

Full year 2021 earnings released: US$0.35 loss per share (vs US$0.27 loss in FY 2020)

Is IceCure Medical Ltd (TLV:ICCM) Potentially Undervalued?

IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022

Icecure Medical Ltd Medical Receives Notice of Intention to Grant A European Patent Covering Its Cryogenic Pump

Is IceCure Medical (TLV:ICCM) In A Good Position To Deliver On Growth Plans?

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Icecure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer

Icecure Medical Ordinary Shares Deleted from Other OTC

IceCure Medical Ltd. Announces Positive Interim Results from ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting

Full year 2020 earnings released: ₪0.11 loss per share (vs ₪0.15 loss in FY 2019)

IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East

New 90-day high: ₪1.48

New 90-day high: ₪0.70

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

New 90-day high: ₪0.72

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

IceCure Medical Ltd has completed a Follow-on Equity Offering in the amount of ILS 20.7 million.

New 90-day low - ₪0.52

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken